DiNAQOR was formed in 2019 by several biotechnology and pharmaceutical experts and specializes in the development of gene therapies. The company is based in Pfäffikon and is now seeking to expand its global research and development activities in the Greater Zurich Area. According to a press release, this fall DiNAQOR will be moving into new premises specially customized to its activities at the Bio-Technopark Schlieren-Zürich.
“This facility is an important expansion of our R&D capabilities and is designed to support the development of gene therapy solutions that transform the lives of patients with heart disease”, comments Thomas Voit, Co-Founder and Chief Scientific Officer at DiNAQOR, in the press release.
DiNAQOR will primarily focus on human induced pluripotent stem cells (iPSC) as well as an engineered heart tissue platform at the new facility covering an overall area of approximately 900 square meters. Thie goal is to improve the understanding of heart diseases. Moreover, new gene-based therapies are to be developed and the company’s approach centered on loco-regional heart perfusion is to be further advanced.
According to Voit, from its new location DiNAQOR is planning to benefit from the large pool of life sciences professionals in the region, which he describes as world class. In addition, he praises the dynamic life sciences environment and proximity to leading companies as other advantages of the location.
Around 45 companies and academic institutions are presently based at the Bio-Technopark Schlieren-Zurich. The facility offers laboratories, office space and infrastructure for research and development activities across a total area of 55,000 square meters.
“DiNAQOR is the first gene therapy company on our campus and we are thrilled to have them join our growing list of premier life sciences companies and academic institutions seeking to advance critical translational research”, comments Mario Jenni, Co-Founder and CEO of the Bio-Technopark Schlieren-Zurich.